Oral Mucositis - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 95 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Oral Mucositis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Oral Mucositis - Pipeline Review, H1 2016', provides an overview of the Oral Mucositis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Oral Mucositis
- The report reviews pipeline therapeutics for Oral Mucositis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Oral Mucositis therapeutics and enlists all their major and minor projects
- The report assesses Oral Mucositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Oral Mucositis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Oral Mucositis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Oral Mucositis Overview 8
Therapeutics Development 9
Pipeline Products for Oral Mucositis - Overview 9
Pipeline Products for Oral Mucositis - Comparative Analysis 10
Oral Mucositis - Therapeutics under Development by Companies 11
Oral Mucositis - Therapeutics under Investigation by Universities/Institutes 12
Oral Mucositis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Oral Mucositis - Products under Development by Companies 16
Oral Mucositis - Products under Investigation by Universities/Institutes 17
Oral Mucositis - Companies Involved in Therapeutics Development 18
Aldeyra Therapeutics, Inc. 18
Cellceutix Corporation 19
Colby Pharmaceutical Company 20
Daewoong Pharmaceutical Co., Ltd. 21
Galera Therapeutics, Inc. 22
Intrexon Corporation 23
Onxeo SA 24
Otsuka Holdings Co., Ltd. 25
ProCertus BioPharm Inc. 26
Soligenix, Inc. 27
Spectrum Pharmaceuticals, Inc. 28
Spherium Biomed S.L. 29
Sucampo Pharmaceuticals, Inc. 30
Oral Mucositis - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
AG-013 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
brilacidin tetrahydrochloride - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
clonidine hydrochloride ER - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
cobiprostone - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
dusquetide - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
GC-4419 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Gene Therapy for Oral Mucositis - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Gene Therapy for Oral Mucositis - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
KIN-219 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
nepidermin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NS-2 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
OralX - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pralatrexate - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
rebamipide - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SP-13004 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Oral Mucositis - Recent Pipeline Updates 62
Oral Mucositis - Dormant Projects 83
Oral Mucositis - Discontinued Products 86
Oral Mucositis - Product Development Milestones 87
Featured News & Press Releases 87
Jan 07, 2016: Galera Therapeutics Announces Fast Track Designation of GC4419 for Prevention of Oral Mucositis 87
Dec 21, 2015: SciClone To Pursue Development Of SGX942 In China Following Soligenix' Report Of Positive Phase 2 Preliminary Results In Oral Mucositis 87
Dec 16, 2015: Soligenix Announces Positive Preliminary Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 88
Dec 04, 2015: Soligenix Provides Clinical Program Updates on SGX942 for December 2015 89
Nov 25, 2015: FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis 89
Oct 22, 2015: Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive for Treatment of Severe Oral Mucositis 90
Oct 19, 2015: Onxeo Validive Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015 91
Sep 09, 2015: Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Succinic Semi-Aldehyde Dehydrogenase Deficiency at the 2015 American Society of Human Genetics Annual Meeting 91
Aug 31, 2015: Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 92
Aug 03, 2015: Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis 92
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 94
Disclaimer 95

List of Tables
Number of Products under Development for Oral Mucositis, H1 2016 9
Number of Products under Development for Oral Mucositis - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Oral Mucositis - Pipeline by Aldeyra Therapeutics, Inc., H1 2016 18
Oral Mucositis - Pipeline by Cellceutix Corporation, H1 2016 19
Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H1 2016 20
Oral Mucositis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 21
Oral Mucositis - Pipeline by Galera Therapeutics, Inc., H1 2016 22
Oral Mucositis - Pipeline by Intrexon Corporation, H1 2016 23
Oral Mucositis - Pipeline by Onxeo SA, H1 2016 24
Oral Mucositis - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 25
Oral Mucositis - Pipeline by ProCertus BioPharm Inc., H1 2016 26
Oral Mucositis - Pipeline by Soligenix, Inc., H1 2016 27
Oral Mucositis - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 28
Oral Mucositis - Pipeline by Spherium Biomed S.L., H1 2016 29
Oral Mucositis - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 30
Assessment by Monotherapy Products, H1 2016 31
Number of Products by Stage and Target, H1 2016 33
Number of Products by Stage and Mechanism of Action, H1 2016 35
Number of Products by Stage and Route of Administration, H1 2016 37
Number of Products by Stage and Molecule Type, H1 2016 39
Oral Mucositis Therapeutics - Recent Pipeline Updates, H1 2016 62
Oral Mucositis - Dormant Projects, H1 2016 83
Oral Mucositis - Dormant Projects (Contd..1), H1 2016 84
Oral Mucositis - Dormant Projects (Contd..2), H1 2016 85
Oral Mucositis - Discontinued Products, H1 2016 86